https://www.thebodypro.com/category/meeting-costs-hiv-care/tag/conference-coverage

The Latest

1,000-Fold Mark-Up for Drug Prices in High Income Countries Blocks Access to HIV, HCV and Cancer Drugs Img

1,000-Fold Mark-Up for Drug Prices in High Income Countries Blocks Access to HIV, HCV and Cancer Drugs

An opening lecture at the 2016 Glasgow HIV Congress challenged the current model of drug pricing in high-income countries by showing mark-ups that are sometimes more than 1,000 times higher than production costs making many medicines largely unafford...

New Antiretrovirals Could Mean Savings Up to $3 Billion by 2025 Img

New Antiretrovirals Could Mean Savings Up to $3 Billion by 2025

The introduction of three new antiretrovirals into treatment programmes in low- and middle-income countries -- tenofovir alafenamide fumarate (TAF), low-dose efavirenz (Sustiva, Stocrin) and dolutegravir (Tivicay, DTG) -- could represent over $3 bill...

Higher Rate of Viral Suppression Found in ACA Enrollees Than in Those Supported Only by Ryan White Img

Higher Rate of Viral Suppression Found in ACA Enrollees Than in Those Supported Only by Ryan White

Low-income HIV-positive people enrolled in Affordable Care Act (ACA) health plans in Virginia had better health outcomes than those receiving care through the state's direct AIDS Drug Assistance Program (ADAP), in which people are typically treated a...

International Activists Confront Gilead Over Hepatitis C Drug Pricing at AIDS 2014 Img

International Activists Confront Gilead Over Hepatitis C Drug Pricing at AIDS 2014

An international group of treatment activists interrupted a session at AIDS 2014 just as Gregg H. Alton, a top official at Gilead Sciences, was about to speak regarding the challenges of expanding global access to the new generation of hepatitis C dr...

Activists Hold Die-In to Protest High Price of Gilead's Hepatitis C Drug Img

Activists Hold Die-In to Protest High Price of Gilead's Hepatitis C Drug

HCV drugs are priced out of reach and out of control.

-- Michel Sidibé, UNAIDS

MELBOURNE, Australia -- Treatment activists at the 20th International AIDS Conference held a die-in to protest the exorbitant pricing of Sovaldi (sofosbuvir), Gilead...

CROI 2014: Fair Pricing Coalition Seeks to Increase Access to HIV and HCV Treatment (Video) Img

CROI 2014: Fair Pricing Coalition Seeks to Increase Access to HIV and HCV Treatment (Video)

Lynda Dee of the Fair Pricing Coalition (FPC) spoke with coworkers Jeff Berry and Murray Penner, as well as David Evans of Project Inform, about access to HIV and hepatitis C (HCV) medications. FPC negotiates with pharmaceutical companies to make the...

Promo Image

High Prices for Antiretrovirals in Middle-Income Countries Outside Africa

Middle-income countries outside of Africa are paying, on average, four times more for antiretrovirals than African countries with similar Gross National Incomes (GNI) according to an analysis presented at IAS 2013.

There have been substantial reduct...

Long-Acting HIV Antiretrovirals May Be Revolutionary. But Will They Be Worth It? Img

Long-Acting HIV Antiretrovirals May Be Revolutionary. But Will They Be Worth It?

A single drug dose, taken no more than once a month, to treat HIV: It's no longer the stuff of idle fantasy. But in a world stuffed with excellent once-a-day drugs, will long-acting meds have value?

Non-African Middle-Income Countries Pay Four Times More for ARVs Than African Middle-Income Countries Img

Non-African Middle-Income Countries Pay Four Times More for ARVs Than African Middle-Income Countries

Compared to wealthy nations and poor nations, "middle-class" countries are getting squeezed out of the HIV treatment market, a new study asserts.

The Social and Economic Determinants of HIV/AIDS: Time for Action Img

The Social and Economic Determinants of HIV/AIDS: Time for Action

As she moved from presentation to presentation at the XIX International AIDS Conference earlier this year, global health consultant Alexis Martin writes that she "was disappointed to find that discussion focused more on describing the problem than id...